Thinking of bosentan repurposing – A study on dehydration and amorphization - Université de Lille Accéder directement au contenu
Article Dans Une Revue International Journal of Pharmaceutics Année : 2022

Thinking of bosentan repurposing – A study on dehydration and amorphization


New clinical indications for an orphan drug bosentan are prompting the improvement of the drug formulation. Since bosentan is available as monohydrate, the information on its anhydrous form together with the assessment of its glass forming ability is necessary when developing enabling formulations. The aim of this research was, therefore, to analyze the phenomena occurring upon dehydration and amorphization of bosentan. The anhydrous form was obtained by a thermal treatment of the monohydrate and characterized for the first time using DSC and XRD. Two stable amorphous forms were prepared by cooling of the melt and high energy ball milling (Tg = 82 ⁰C). The chemical stability of milled bosentan was evaluated using ATR-IR and 1H NMR as well. The kinetics of bosentan amorphization was established. It was stated that bosentan could be easily amorphized. Importantly, even if the system was semiamorphous, there was no recrystallization while heating. The concentration–time curves recorded in biorelevant media, confirmed the beneficial effect of amorphization on the dissolution of bosentan. Yet, the amorphous form recrystallized into the monohydrate form in the gastric milieu. This phenomenon was accompanied by a reversible color change from yellow, which is typical of bosentan glass, to creamywhite that is characteristic of the crude crystalline drug
Fichier principal
Vignette du fichier
1-s2.0-S037851732200401X-main.pdf (3.26 Mo) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-03707272 , version 1 (28-06-2022)




Anna Krupa, Florence Danede, Agnieszka Węgrzyn, Dorota Majda, Jean-François Willart. Thinking of bosentan repurposing – A study on dehydration and amorphization. International Journal of Pharmaceutics, 2022, 622, pp.121846. ⟨10.1016/j.ijpharm.2022.121846⟩. ⟨hal-03707272⟩
13 Consultations
16 Téléchargements



Gmail Mastodon Facebook X LinkedIn More